Seroatlas · Human Serome Atlas

VRTN

Vertnin

Also known as: C14orf115, FLJ10811, vertnin, VRTN_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9H8Y1
Gene: VRTN
Ensembl: ENSG00000133980
Chromosome: 14
Canonical length: 702 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm

OverviewNCBI Gene

Predicted to enable sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be located in nucleus. Predicted to be active in chromatin. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

702 residues, UniProt reviewed canonical sequence.

>Q9H8Y1|VRTN
     1  MTSRNQLVQK VLQELQEAVE CEGLEGLIGA SLEAKQVLSS FTLPTCREGG PGLQVLEVDS
    61  VALSLYPEDA PRNMLPLVCK GEGSLLFEAA SMLLWGDAGL SLELRARTVV EMLLHRHYYL
   121  QGMIDSKVML QAVRYSLCSE ESPEMTSLPP ATLEAIFDAD VKASCFPSSF SNVWHLYALA
   181  SVLQRNIYSI YPMRNLKIRP YFNRVIRPRR CDHVPSTLHI MWAGQPLTSH FFRHQYFAPV
   241  VGLEEVEAEG APGVAPALPA LAPLSSPAKT LELLNREPGL SYSHLCERYS VTKSTFYRWR
   301  RQSQEHRQKV AARFSAKHFL QDSFHRGGVV PLQQFLQRFP EISRSTYYAW KHELLGSGTC
   361  PALPPREVLG MEELEKLPEE QVAEEELECS ALAVSSPGMV LMQRAKLYLE HCISLNTLVP
   421  YRCFKRRFPG ISRSTYYNWR RKALRRNPSF KPAPALSAAG TPQLASVGEG AVIPWKSEAE
   481  EGAGNATGED PPAPGELLPL RMPLSRWQRR LRRAARRQVL SGHLPFCRFR LRYPSLSPSA
   541  FWVWKSLARG WPRGLSKLQV PVPTLGKGGQ EAEEKQEKEA GRDVTAVMAP PVGASSEDVE
   601  GGPSREGALQ EGATAQGQPH SGPLLSQPVV AAAGGRDGRM LVMDMIATTK FKAQAKLFLQ
   661  KRFQSKSFPS YKEFSALFPL TARSTYYMWK RALYDGLTLV DG

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against VRTN can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.44
Highest tissue expression: 1.6 nTPM

Expression across tissuesHPA

Tissue

testis: 1.6 nTPM
epididymis: 1.4 nTPM
lymph node: 0.4 nTPM
ovary: 0.4 nTPM
tonsil: 0.4 nTPM
duodenum: 0.2 nTPM

Single-cell type

tuft cells: 12 nCPM
oocytes: 9.2 nCPM
early primary spermatocytes: 5.8 nCPM
epididymal principal cells: 4.4 nCPM
paneth cells: 3.9 nCPM
early spermatids: 3.7 nCPM

Immune cell

neutrophil: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM

Brain region

basal ganglia: 0.6 nTPM
medulla oblongata: 0.6 nTPM
cerebellum: 0.5 nTPM
cerebral cortex: 0.5 nTPM
hippocampal formation: 0.5 nTPM
hypothalamus: 0.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.26
gnomAD pLI: 0.99
gnomAD missense Z: 1.67
DepMap mean gene effect: 0
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

regulation of transcription by RNA polymerase II

Molecular functions

sequence-specific DNA binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

Trp repressor/replication initiator
Vertnin-like
Vertnin-like, ovarian tumor domain

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads VRTN as an antibody target. Whether an autoantibody or antibody against VRTN could matter depends on whether native VRTN is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

VRTN is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label VRTN as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...